Cagrisema vs Zepbound
Which Is Right for You? Complete Comparison (2026)
CagriSema (cagrilintide + semaglutide) vs Zepbound (tirzepatide): compare mechanisms, late-stage data, and current regulatory status in 2026.
Cagrisema vs Zepbound: At a Glance
- ✓Combination: cagrilintide (amylin analogue) + semaglutide (GLP-1)
- ✓Amylin + GLP-1 dual satiety pathway activation
- ✓~22.7% weight loss in phase 2 (vs 15.8% semaglutide alone)
- ✓Single weekly injection combining both agents
- ✓Phase 3 REDEFINE trials ongoing — Novo Nordisk
- ✓Dual GIP + GLP-1 receptor agonist — first in class
- ✓GIP agonism enhances insulin sensitivity in adipose tissue
- ✓~21% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg)
- ✓GIP may moderate GI side effects vs GLP-1-only drugs
- ✓Half-life ~5 days — once-weekly injection
Detailed Comparison
| Feature | Cagrisema | Zepbound |
|---|---|---|
| Mechanism | Amylin/GLP-1 combination | Dual GIP/GLP-1 receptor agonistBest |
| Dosing | Cagrilintide 2.4 mg + semaglutide 2.4 mg SC weekly | 2.5-15 mg SC weekly |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Half-life | Cagrilintide ~7 days; semaglutide ~7 days | ~5 days |
| FDA Status | Not FDA-approved — phase 3 clinical trials | FDA-approved: Mounjaro (T2D), Zepbound (obesity) |
| Key Trial | Frias JP et al. Lancet 2023 — phase 2 combination trial | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss |
| Side Effects | GI effects similar to semaglutide; injection site reactions | Nausea (31%), vomiting, diarrhea, constipation |
Which Should You Choose?
CagriSema (Cagrilintide + Semaglutide) (amylin/glp-1 combination) and Tirzepatide (dual gip/glp-1 receptor agonist) serve different clinical roles despite both being in the Combination anti-obesity space. CagriSema (Cagrilintide + Semaglutide) fixed-dose combination of cagrilintide (long-acting amylin analogue) and semaglutide (glp-1 agonist) that targets two satiety pathways for enhanced weight loss. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Cagrisema and Zepbound
Choosing between Cagrisema and Zepbound depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Cagrisema and Zepbound is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Cagrisema vs Zepbound: Frequently Asked Questions
CagriSema (Cagrilintide + Semaglutide) is an amylin/glp-1 combination while Tirzepatide is a dual gip/glp-1 receptor agonist. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
CagriSema (Cagrilintide + Semaglutide) works as a amylin/glp-1 combination (Cagrilintide 2.4 mg + semaglutide 2.4 mg SC weekly), while Tirzepatide is a dual gip/glp-1 receptor agonist (2.5-15 mg SC weekly). They have different half-lives (Cagrilintide ~7 days; semaglutide ~7 days vs ~5 days), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Cagrisema or Zepbound in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.